Clinical Trials Logo

Intestinal Permeability clinical trials

View clinical trials related to Intestinal Permeability.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06262880 Recruiting - Clinical trials for Intestinal Permeability

Dietary Supplementation on Gastrointestinal Barrier Function

Start date: February 6, 2024
Phase: N/A
Study type: Interventional

The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels on parameters of gastrointestinal (GI) health in otherwise generally healthy adults with risk factors (high BMI and waist circumference) for increased GI permeability. The primary hypothesis is that supplementation with plant derived phenolics will improve gut health compared to placebo.

NCT ID: NCT05257200 Recruiting - Clinical trials for Bariatric Surgery Candidate

Gut Permeability and Bariatric-metabolic Surgery

Start date: May 1, 2021
Phase:
Study type: Observational

Increased intestinal permeability and dysbiosis have been causally associated with NAFLD and NASH progression. However, to date, there are no systematic studies, on the effect of bariatric-metabolic surgery on intestinal permeability and dysbiosis in the context of NAFLD development.

NCT ID: NCT04979130 Recruiting - Type 2 Diabetes Clinical Trials

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

SIB
Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

This study plans to learn more about the effect of semaglutide once weekly on intestinal permeability in individuals with type 2 diabetes.

NCT ID: NCT04543877 Recruiting - Inflammation Clinical Trials

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

Start date: September 27, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine if adding dietary fiber, such as inulin, to a diet that does not have enough fiber would raise the levels of potentially beneficial bacteria, such as Bifidobacterium, in the gut. There is evidence to suggest that these microbes can affect gut health and immune response, including to vaccines. The investigators will examine how inulin in the diet (compared to the maltodextrin control) (1) causes changes in the composition and function of the gut microbes, (2) reduces gut inflammation and gut leakiness caused by the vaccine, (3) increases immune response to vaccination, and (4) changes the expression of important adhesion molecules on the surface of white blood cells. Intestinal and whole-body responses will be measured in all participants.

NCT ID: NCT04109352 Recruiting - Malnutrition, Child Clinical Trials

Labelled Carbon Sucrose Breath Test (13C-SBT) as a Marker of Environmental Enteropathy

SBT4EE
Start date: September 1, 2019
Phase:
Study type: Observational

Linear growth failure, a manifestation of chronic undernutrition in early childhood, is a recalcitrant problem in resource constrained settings. The underlying causes of growth failure are multifactorial, but persistent and recurrent infection and inflammation of the gastrointestinal tract and immune activation, a condition commonly referred to as environmental enteropathy, is an important contributor. A highly enriched 13C-Sucrose Breath Test, a measure of sucrase-isomaltase activity, will be evaluated as a non-invasive biomarker of environmental enteropathy, and more specifically of intestinal brush border enzyme activity in 6 resource poor countries (Bangladesh, India, Jamaica, Kenya, Peru and Zambia) in 100 volunteers aged 12-15 months (total n=600) and evaluated relative to the lactose rhamnose test and linear and ponderal growth over a 3-6 month period following biomarker assessment. Field usability will also be assessed.